{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:nanoalvand-company",
    "identifier": "hg:company:nanoalvand-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:17+00:00",
    "name": "NanoAlvand Company",
    "slug": "nanoalvand-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/nanoalvand-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/nanoalvand-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/nanoalvand-company",
    "summary": "",
    "machine_summary": "NanoAlvand Company NanoAlvand Company is a private knowledge-based pharmaceutical manufacturer with manufacturing activity linked to Alborz Province and a portfolio focused on advanced and high-potency medicines. In the Hormuz Group company graph, it matters because it connects Iran's oncology-drug localization, advanced formulation capability, pharmaceutical R&D, regulatory compliance, and substitution of imported high-value medicines. Its profile is more technology-intensive than ordinary generic drug production. NanoAlvand is relevant for investors assessing Iran's advanced pharmaceutical manufacturing, oncology and specialty-drug demand, high-potency production capability, import substitution, technology gaps, and export potential in complex generics. It can support analysis of how local firms move from basic generics toward higher-value medicines under regulatory and sanctions constraints. Due diligence should verify ownership, GMP status, product registrations, current manufacturing sites, active pharmaceutical ingredient sourcing, export registrations, pharmacovigilance systems, intellectual-property exposure, quality-control capacity, and international market access. NanoAlvand Company develops and manufactures high-potency and specialized pharmaceutical products, with product fields including oncology, neurology, rheumatology, and other advanced therapeutic categories. Its activity is linked to complex generics, hazardous drug manufacturing, sterile or controlled production environments, regulatory documentation, clinical access, import substitution, and high-value pharmaceutical technology. province: Alborz industry: Healthcare & Pharma, Pharmaceuticals market: Consumer Demand, Healthcare, Materials, Supply Chains challenges: Compliance, Data Gaps, Import Dependence, Technology Gap company_type: Manufacturer, Private Company city: Karaj",
    "published_at": "2026-06-28T20:28:55+00:00",
    "modified_at": "2026-06-28T20:28:55+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 198,
                "name": "Alborz",
                "slug": "alborz",
                "url": "https://hormuz.group/provinces/alborz/"
            }
        ],
        "industry": [
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 34,
                "name": "Consumer Demand",
                "slug": "consumer-demand",
                "url": "https://hormuz.group/market/consumer-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 73,
                "name": "Materials",
                "slug": "materials",
                "url": "https://hormuz.group/market/enterprise-demand/materials/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 187,
                "name": "Data Gaps",
                "slug": "data-gaps",
                "url": "https://hormuz.group/challenges/operational-risks/data-gaps/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 299,
                "name": "Manufacturer",
                "slug": "manufacturer",
                "url": "https://hormuz.group/company-type/manufacturer/"
            },
            {
                "id": 307,
                "name": "Private Company",
                "slug": "private-company",
                "url": "https://hormuz.group/company-type/private-company/"
            }
        ],
        "city": [
            {
                "id": 391,
                "name": "Karaj",
                "slug": "karaj",
                "url": "https://hormuz.group/cities/karaj/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "Alborz",
        "industry": "Healthcare & Pharma, Pharmaceuticals",
        "market": "Consumer Demand, Healthcare, Materials, Supply Chains",
        "challenges": "Compliance, Data Gaps, Import Dependence, Technology Gap",
        "company_type": "Manufacturer, Private Company",
        "city": "Karaj"
    },
    "fields_summary": {
        "legal_name": "NanoAlvand Pharmaceutical Company",
        "website": "https://nanoalvand.com",
        "city": "Karaj, Alborz Province, Iran",
        "ticker_symbol": "",
        "listing_status": "private",
        "products_services": "NanoAlvand Company develops and manufactures high-potency and specialized pharmaceutical products, with product fields including oncology, neurology, rheumatology, and other advanced therapeutic categories. Its activity is linked to complex generics, hazardous drug manufacturing, sterile or controlled production environments, regulatory documentation, clinical access, import substitution, and high-value pharmaceutical technology.",
        "export_relevance": "medium",
        "short_profile": "NanoAlvand Company is a private knowledge-based pharmaceutical manufacturer with manufacturing activity linked to Alborz Province and a portfolio focused on advanced and high-potency medicines. In the Hormuz Group company graph, it matters because it connects Iran's oncology-drug localization, advanced formulation capability, pharmaceutical R&D, regulatory compliance, and substitution of imported high-value medicines. Its profile is more technology-intensive than ordinary generic drug production.",
        "investment_relevance": "NanoAlvand is relevant for investors assessing Iran's advanced pharmaceutical manufacturing, oncology and specialty-drug demand, high-potency production capability, import substitution, technology gaps, and export potential in complex generics. It can support analysis of how local firms move from basic generics toward higher-value medicines under regulatory and sanctions constraints. Due diligence should verify ownership, GMP status, product registrations, current manufacturing sites, active pharmaceutical ingredient sourcing, export registrations, pharmacovigilance systems, intellectual-property exposure, quality-control capacity, and international market access."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "NanoAlvand Pharmaceutical Company",
        "city": "Karaj, Alborz Province, Iran",
        "ticker_symbol": "",
        "export_relevance": "medium",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "private",
        "last_updated": "29/06/2026",
        "website": "https://nanoalvand.com",
        "products_services": "NanoAlvand Company develops and manufactures high-potency and specialized pharmaceutical products, with product fields including oncology, neurology, rheumatology, and other advanced therapeutic categories. Its activity is linked to complex generics, hazardous drug manufacturing, sterile or controlled production environments, regulatory documentation, clinical access, import substitution, and high-value pharmaceutical technology.",
        "short_profile": "NanoAlvand Company is a private knowledge-based pharmaceutical manufacturer with manufacturing activity linked to Alborz Province and a portfolio focused on advanced and high-potency medicines. In the Hormuz Group company graph, it matters because it connects Iran's oncology-drug localization, advanced formulation capability, pharmaceutical R&D, regulatory compliance, and substitution of imported high-value medicines. Its profile is more technology-intensive than ordinary generic drug production.",
        "investment_relevance": "NanoAlvand is relevant for investors assessing Iran's advanced pharmaceutical manufacturing, oncology and specialty-drug demand, high-potency production capability, import substitution, technology gaps, and export potential in complex generics. It can support analysis of how local firms move from basic generics toward higher-value medicines under regulatory and sanctions constraints. Due diligence should verify ownership, GMP status, product registrations, current manufacturing sites, active pharmaceutical ingredient sourcing, export registrations, pharmacovigilance systems, intellectual-property exposure, quality-control capacity, and international market access.",
        "source_note": "Based on public company, official-company, pharmaceutical-sector, oncology, high-potency manufacturing, product, and market-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 33
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 28
        },
        "ticker_symbol": {
            "type": "string",
            "present": false,
            "length": 0
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 6
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 7
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 22
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 433
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 505
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 672
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 243
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, official-company, pharmaceutical-sector, oncology, high-potency manufacturing, product, and market-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026"
    }
}